El tratamiento con Jusvinza disminuye la hiperinflamación y la hipercoagulación en pacientes críticos con la COVID-19
Rafael Venegas Rodríguez, María del Carmen Domínguez Horta, Anadys Segura Fernández, Rubén Peña Ruiz, Aliusha Rittoles Navarro(Hospital Oncológico Docente "Conrado Benítez García"), Gerardo Guillén(Hunan City University), Deyli Chacón Montano, Leticia Rosario Cruz(Hospital Oncológico Docente "Conrado Benítez García"), L. Aguilera, Mabel Hernández-Cedeño(Centro de Ingeniería Genética y Biotecnología), Gillian Martínez‐Donato(Centro de Ingeniería Genética y Biotecnología), Inti Grecesqui Cruz, Anabel Serrano Díaz(Centro de Ingeniería Genética y Biotecnología), Raúl Santana Sánchez
DOAJ (DOAJ: Directory of Open Access Journals)
November 23, 2021
Cited by 1
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134